Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 7171-year-old woman presents to her primary care physician for a scheduled medication management visit. She has a documented history of severe postmenopausal osteoporosis, which was complicated by a painful L2L2 vertebral compression fracture two years ago. At that time, a dual-energy x-ray absorptiometry (DEXA) scan revealed a T-score of −3.5-3.5 at the lumbar spine, and she was subsequently initiated on daily subcutaneous teriparatide therapy. She has been fully compliant with the medication and reports no new bone pain, back pain, or falls. Today marks exactly 2424 months of continuous teriparatide treatment.

Current laboratory studies:
Calcium: 9.5 mg/dL9.5 \text{ mg/dL}
Phosphorus: 3.6 mg/dL3.6 \text{ mg/dL}
Creatinine: 0.8 mg/dL0.8 \text{ mg/dL}
Alkaline phosphatase: 115 U/L115 \text{ U/L}
2525-hydroxyvitamin D: 45 ng/mL45 \text{ ng/mL}

A repeat DEXA scan performed this week demonstrates a T-score of −2.3-2.3 at the lumbar spine and −2.5-2.5 at the total hip.

Which of the following is the most appropriate next step in the management of this patient's osteoporosis?

  1. Discontinue teriparatide and initiate oral alendronate therapyCevap
  2. B
    Continue teriparatide for an additional 12 months to maintain bone density
  3. C
    Discontinue teriparatide and observe with a repeat bone density scan in 12 months
  4. D
    Continue teriparatide and add subcutaneous denosumab to the treatment regimen
  5. E
    Discontinue teriparatide and measure serum C-telopeptide before selecting further therapy

Cevap

The patient should have teriparatide discontinued and immediately begin an antiresorptive agent, such as oral alendronate, to preserve her bone mineral density.
The correct course of action is to stop the anabolic agent and immediately begin an antiresorptive agent. Teriparatide is a recombinant fragment of human parathyroid hormone that powerfully stimulates bone formation. However, its use is strictly capped at a cumulative lifetime duration of 24 months. Furthermore, because teriparatide does not embed into the bone matrix, its discontinuation triggers an accelerated phase of bone resorption. To preserve the bone architecture and density gained during the 24-month anabolic window, clinical guidelines mandate sequential therapy with a potent antiresorptive medication, such as a bisphosphonate (e.g., alendronate) or denosumab.

Adım Adım Çözüm

1
Evaluate the current duration and status of the patient's pharmacological therapy.
The patient has completed exactly 24 months of teriparatide, which is the maximum lifetime duration recommended.
Teriparatide (a parathyroid hormone analog) must be stopped at 24 months due to long-term safety concerns (e.g., theoretical osteosarcoma risk) and lack of efficacy data beyond this timeframe.
2
Determine the physiologic consequence of stopping the current medication.
Unlike bisphosphonates, anabolic agents do not persist in the bone matrix. Stopping teriparatide results in a rapid decline in bone mineral density (BMD).
Withdrawal of the anabolic stimulus leads to accelerated osteoclast-mediated bone resorption.
3
Select the appropriate sequential pharmacological intervention.
Initiate an antiresorptive agent (such as a bisphosphonate or denosumab).
Antiresorptive therapy must follow anabolic therapy to lock in and consolidate the substantial BMD gains achieved over the preceding two years.

Anahtar Kavram

Patients completing a 2-year course of an anabolic agent (e.g., teriparatide) must be sequentially transitioned to an antiresorptive agent (e.g., alendronate or denosumab) to prevent rapid bone loss and maintain fracture risk reduction.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru